Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue

Abstract Liposomes have been used to diagnose and treat cancer and, to a lesser extent, cardiovascular disease. We previously showed the uptake of anionic liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits within lipid pools. However, the cellular distribution of anionic liposomes in atherosclerotic plaque remains undescribed. In addition, how anionic liposomes are absorbed into atherosclerotic plaque is unclear. We investigated the uptake and distribution of anionic liposomes in atherosclerotic plaque in aortic tissues from apolipoprotein E-deficient (ApoE–/–) mice. To facilitate the tracking of liposomes, we used liposomes containing fluorescently labeled non-silencing small interfering RNA. Confocal microscopy analysis showed the uptake of anionic liposomes into atherosclerotic plaque and colocalization with macrophages. Transmission electron microscopy analysis revealed anionic liposomal accumulation in macrophages. To investigate how anionic liposomes cross the local endothelial barrier, we examined the role of clathrin-mediated endocytosis in human coronary artery endothelial cells (HCAECs) treated with or without the inflammatory cytokine tumor necrosis factor (TNF)-α. Pretreatment with amantadine, an inhibitor of clathrin-mediated endocytosis, significantly decreased liposomal uptake in HCAECs treated with or without TNF-α by 77% and 46%, respectively. Immunoblot analysis showed that endogenous clathrin expression was significantly increased in HCAECs stimulated with TNF-α but was inhibited by amantadine. These studies indicated that clathrin-mediated endocytosis is partly responsible for the uptake of liposomes by endothelial cells. Our results suggest that anionic liposomes target macrophage-rich areas of vulnerable plaque in ApoE–/– mice; this finding may lead to the development of novel diagnostic and therapeutic strategies for treating vulnerable plaque in humans.

[1]  Peter Seizer,et al.  Platelets in Inflammation and Atherogenesis , 2015, Front. Immunol..

[2]  J. Jawień.  The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis. , 2012, Current pharmaceutical biotechnology.

[3]  M. Bennett,et al.  Aging and Atherosclerosis: Mechanisms, Functional Consequences, and Potential Therapeutics for Cellular Senescence , 2012, Circulation research.

[4]  J. Feig,et al.  Macrophages, dendritic cells, and regression of atherosclerosis , 2012, Front. Physio..

[5]  Prerna Bhargava,et al.  Role and function of macrophages in the metabolic syndrome. , 2012, The Biochemical journal.

[6]  Harvey T. McMahon,et al.  Molecular mechanism and physiological functions of clathrin-mediated endocytosis , 2011, Nature Reviews Molecular Cell Biology.

[7]  Beñat Mallavia,et al.  Animal Models of Cardiovascular Diseases , 2011, Journal of biomedicine & biotechnology.

[8]  F. Clubb,et al.  Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits , 2010, Vascular medicine.

[9]  Anil K Sood,et al.  Therapeutic Targeting of ATP7B in Ovarian Carcinoma , 2009, Clinical Cancer Research.

[10]  Han-Chung Wu,et al.  Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors* , 2009, Journal of Biological Chemistry.

[11]  Renu Virmani,et al.  Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. , 2009, Journal of the American College of Cardiology.

[12]  E. Moore,et al.  Amantadine inhibits platelet-activating factor induced clathrin-mediated endocytosis in human neutrophils. , 2009, American journal of physiology. Cell physiology.

[13]  S. Harper,et al.  Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx , 2009, Cardiovascular research.

[14]  P. Libby,et al.  The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models , 2008, Nature Reviews Immunology.

[15]  J. Ruysschaert,et al.  Cationic lipid/DNA complexes induce TNF-alpha secretion in splenic macrophages. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  C. Schindler,et al.  NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. , 2006, The Journal of clinical investigation.

[17]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[18]  Zahi A Fayad,et al.  Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. , 2005, Journal of the American College of Cardiology.

[19]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[20]  E. Topol,et al.  Molecular mechanisms of myocardial infarction. , 2005, Current problems in cardiology.

[21]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[22]  J. Granada,et al.  Vulnerable plaque paradigm: Prediction of future clinical events based on a morphological definition , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[23]  D. McPherson,et al.  Intravascular ultrasound molecular imaging of atheroma components in vivo. , 2004, Journal of the American College of Cardiology.

[24]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[25]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[26]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[27]  Lucas Pelkmans,et al.  Endocytosis Via Caveolae , 2002, Traffic.

[28]  S. Yusuf,et al.  Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. , 2001, Circulation.

[29]  F. Brodsky,et al.  Biological basket weaving: formation and function of clathrin-coated vesicles. , 2001, Annual review of cell and developmental biology.

[30]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[31]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[32]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[33]  N. Phillips,et al.  Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. , 1997, Biochimica et biophysica acta.

[34]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[35]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[36]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[37]  N. Maeda,et al.  Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Lopez-Berestein.  Liposomes as carriers of antimicrobial agents , 1987, Antimicrobial Agents and Chemotherapy.

[39]  D. Steinberg,et al.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Steinberg,et al.  Macrophage Oxidation of Low Density Lipoprotein Generates a Modified Form Recognized by the Scavenger Receptor , 1986, Arteriosclerosis.

[41]  J. D. Smith,et al.  Mouse models of atherosclerosis. , 1998, Laboratory animal science.

[42]  I. Mellman.  Endocytosis and molecular sorting. , 1996, Annual review of cell and developmental biology.

[43]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[44]  G. Lopez-Berestein.  Liposomes in infectious diseases: present and future. , 1989, Current clinical topics in infectious diseases.

[45]  G. Lopez-Berestein,et al.  Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. , 1984, Cancer drug delivery.

[46]  E. Hersh,et al.  Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. , 1984, Cancer research.